Skip to main content
. 2011 Jun 15;6(6):e21215. doi: 10.1371/journal.pone.0021215

Figure 11. Antiviral effect of AmiRs delivered by folate-labeled pRNA-AmiR monomers and heterodimers.

Figure 11

HeLa cells were treated with folate-labeled or non-labeled pRNA-AmiR monomers or heterodimers and infected with CVB3. The non-treated sample, F-pRNA-Ba'/pRNA-Ab'(AmiR-S) treated cells and non-labeled pRNA-AmiR-1 treated sample were used as three controls. Cell morphology was observed under a phase contrast microscope. Dying cells appeared rounding and detachment (A). Cell viability was also quantified by MTS assay (B). Anti-CVB3 effect was evaluated by Western blot analysis of VP-1 protein (C) and viral plaque assay of CVB3 particles (D).